

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: **SureNano Science Ltd.** (the "Issuer").

Trading Symbol: **SURE**

Number of Outstanding Listed Securities: **21,457,800 common shares and 2,200,000 options.**

Date: **June 2, 2022**

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**During the month of May 2022, the Issuer continued its business activities and focused on its business of the sale and distribution of SureNano™ surfactant.**

2. Provide a general overview and discussion of the activities of management.

**See Item 1.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None.**

8. Describe the acquisition of new customers or loss of customers.

**None.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.  
**None.**
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.  
**None.**
11. Report on any labour disputes and resolutions of those disputes if applicable.  
**None.**
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.  
**None.**
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.  
**None.**
14. Provide details of any securities issued and options or warrants granted.  
**None.**
15. Provide details of any loans to or by Related Persons.  
**None.**
16. Provide details of any changes in directors, officers or committee members.  
**None.**
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer's prospectus under the title "Risk Factors", which is available on SEDAR at [www.sedar.com](http://www.sedar.com).**

**In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Issuer to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Issuer's business or ability to raise funds.**

**The Issuer's business, operations and financial condition could be materially adversely affected by the outbreak of epidemics, pandemics or other health crises, such as COVID-19. As at the date of this progress report, the global reactions to the spread of COVID-19 which led to, among other things, significant restrictions on travel, quarantines, temporary business closures and a general reduction in consumer activity. The risks to the Issuer of such public health crises also include risks to employee and contractor health and safety and a slowdown or temporary suspension of operations in geographic locations impacted by an outbreak.**

**At this point, the extent to which COVID-19 may impact the Issuer is uncertain; however, it is possible that COVID-19 could have a material adverse effect on the timing and cost of the business objectives and milestones and the Company's business, results of operations and financial condition.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: June 2, 2022

Charles MaLette  
Name of Director or Senior Officer

"Charles MaLette"  
Signature

President, CEO and Director  
Official Capacity

<b>Issuer Details</b>		
Name of Issuer <b>SureNano Science Ltd.</b>	For - Month End <b>May 2022</b>	Date of Report YYYY/MM/DD <b>2022/06/02</b>
Issuer Address <b>350 – 1650 West 2<sup>nd</sup> Avenue,</b>		
City/Province/Postal Code <b>Vancouver, BC V6J 1H4</b>	Issuer Fax No. <b>N/A</b>	Issuer Telephone No. <b>(604) 428-5171</b>
Contact Name <b>Charles MaLette</b>	Contact Position <b>President, CEO, Director</b>	Contact Telephone No. <b>(604) 428-5171</b>
Contact Email Address <b>info@surenano.com</b>	Web Site Address <a href="http://www.surenano.com">www.surenano.com</a>	